Processa Pharmaceuticals Inc

For the period ended Dec 31, 2023. Filed Mar 29, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 29, 2024

PCSA$1.95+1.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

	December 31, 2023	December 31, 2022
ASSETS
Current Assets
Cash and cash equivalents	$4,706,197	$6,503,595
Prepaid expenses and other	926,300	1,883,134
Total Current Assets	5,632,497	8,386,729
Property and Equipment, net	2,554	-
Other Assets
Operating lease right-of-use assets, net	146,057	227,587
Other	5,535	5,535
Total Other Assets	151,592	233,122
Total Assets	$5,786,643	$8,619,851
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Current maturities of operating lease liability	$83,649	$78,896
Accounts payable	311,617	327,548
Due to licensor	189,000	189,000
Due to related parties	39	51
Accrued expenses	146,274	403,061
Total Current Liabilities	730,579	998,556
Non-current Liabilities
Non-current operating lease liability	66,905	150,554
Total Liabilities	797,484	1,149,110
Commitments and Contingencies	-	-
Stockholders’ Equity
Common stock, par value $0.0001, 100,000,000 shares authorized; 1,291,000 issued and 1,286,000 outstanding at December 31, 2023 and 806,774 issued and 801,774 outstanding at December 31, 2022	129	80
Additional paid-in capital	80,658,111	72,018,222
Treasury stock	(300,000)	(300,000)
Accumulated deficit	(75,369,081)	(64,247,561)
Total Stockholders’ Equity	4,989,159	7,470,741
Total Liabilities and Stockholders’ Equity	$5,786,643	$8,619,851

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.